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Introduction
Cancer is a group of diseases characterized by an uncontrolled growth of abnormal
cells which tend to proliferate in an uncontrolled way. The term ’cancer’ represents
numerous disease types, depending on the type of cell from which the tumor em-
anates. This, along with the grade of tumor maturity determines its ability to grow,
invade adjacent tissues, and spread throughout the body.
Cancer diseases represent a serious public health problem since they affect many
people and are a frequent cause of death. According to a worldwide statistics from
the ”World cancer report 2008”, there were 12.4 million new cancer cases diagnosed
and 7.6 million deaths reported from the disease in 2008 [1].
The 5-year relative survival rate for all cancers diagnosed between 2001 and 2007 is
67%, up from 49% in 1975-1977. The improvement in survival reflects both progress
in diagnosing certain cancers at an earlier stage and improvements in treatment [2].
Tumor spread, type, and differentiation are generally the most important factors
for determining the prognosis and choice of treatment [3]. Treatments for cancer
include surgery, chemotherapy, radiotherapy, hormonal therapies and biological ther-
apies. Treatment can be given with the aim of curing the cancer, controlling it or
relieving symptoms.
People are often given more than one type of treatment for their cancer. Radio-
therapy is commonly used as an essential component in the management of cancer
patients, either alone or in combination with surgery or chemotherapy. This treat-
ment modality is often given with the aim of destroying a tumor and curing the
cancer (curative or radical radiotherapy), or when it’s not possible to cure a cancer,
radiotherapy may be given to relieve symptoms such as pain (palliative treatment).
The chance of tumor eradication with radiation depends on tumor-related fac-
tors, such as radio-sensitivity, volume, location and dissemination path, as well as
factors related to the irradiation modality, such as the treatment plan and target-
ing accuracy. Higher doses of radiation generally give improved local control and
possibly longer disease-free survival, but it is important to ensure that the radiation
tolerance of adjacent normal tissues is not exceeded.
In the quest for ways to improve radiotherapy effectiveness, new approaches
have been explored. Intensity-modulated radiation therapy, hadrontherapy and syn-
chrotron radiation therapies are some examples.
Within this contest, spatially fractionated radiotherapy techniques are poten-
tially able to spare normal tissues along with giving large amount of dose at the
target.
In this work, Monte Carlo simulation of the dose deposition for two types of
spatially radiotherapy techniques, Minibeam Radiation Therapy (MBRT) and Grid
therapy, have been performed. The two techniques combine submillimetric field
sizes and spatial fractionation of the dose. The resulting biological effects appear to
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challenge many of the current paradigms in radiation therapy. Remarkable healthy
tissue resistance to very high doses in one fraction was observed in several biological
investigations performed during the last two decades. Other than x-rays radia-
tion therapy techniques, other methods are available or in development, such as
hadrontherapy which is an advanced external RT technique that uses charged par-
ticles. Particle beams have physical and radiobiological characteristics which differ
markedly from those of conventional radiotherapy beams composed of γ-rays or x-
rays: charged hadrons interact more readily with matter (have enhanced ballistic
selectivity) allowing well-defined distribution of the dose in depth; while ions deposit
a large fraction of their energy at the end of their track, resulting in intense local
ionization that is considered highly effective against radiation-resistant tumors.
Using particle beams instead of x-rays, the ballistic properties of charged parti-
cles and their increased biological efficiency are added to the advantages of spatially
fractionated techniques.
The MBRT potential to achieve high degrees of tumor control with less invasive
effects on the surrounding healthy tissues, and the properties of hadrontherapy, are
discussed in Chapter 1.
A brief introduction to radiobiology, which is fundamental to understanding the
biological advantages of the use of hadrons, is provided in Chapter 2.
To perform Monte Carlo simulation, the GATE code was used. The description
of the physics and the Monte Carlo code used, are given in Chapter 3.
The results obtained for MBRT with carbon and oxygen are presented in Chapter
4 and 5 respectively. On those chapters, all the data and calculations performed,
are shown. The results related to carbon and oxygen are compared in Chapter 6.
The last chapter is devoted to simulations and their results in grid therapy
implemented with protons.
Chapter 1
Principles of spatially fractionated
radiotherapy
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1.1 Radiotherapy: an overview
Radiotherapy, or radiation therapy (RT), is the treatment of cancer and other dis-
eases with ionizing radiation. Ionizing radiation deposits energy that injures or
destroys cells by damaging their DNA, thus making it impossible for them to repro-
duce. Radiation therapy can damage normal cells as well as cancer cells. Therefore,
treatment must be carefully planned to minimize side effects. This is one of the
greatest challenges of radiotherapy: to minimize damage to normal cells through
the delivery of an adequate dose aimed to destroy tumor cells and spare their nor-
mal counterparts.
X-rays, gamma rays and charged particles are types of radiation used for cancer
treatment. The radiation may be delivered by a machine outside the body (external-
beam radiation) pointing the part of the body to be treated after the careful planning
of where the generated beams will deposit their energy. Radiotherapy can also be
given internally by drinking a liquid isotope, delivering it by intravenous injection or
by placing a radioactive implant directly into or close to a tumor (internal radiation
therapy, also called brachytherapy). The type of radiation therapy to use depends
on the type and size of cancer, on his location, how close the cancer is to normal
tissues that are sensitive to radiation, and how far into the body the radiation needs
to travel.
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Conventional external beam radiation therapy is used in the 80% of the cases
and is delivered, for the most, using linear accelerator machines. Depending on the
machine specifications, the energy can be varied with a range of 4-25 MV [4].
In order to reduce the side effects of the treatment, a selective tumor destruction
can be achieved enhancing the precision in dose delivery. Different special techniques
have been developed with this aim, between others:
• Three dimensional conformal radiotherapy (3-D CRT);
• Intensity modulated radiation therapy (IMRT);
• Image guided radiation therapy (IGRT);
• Respiratory gated radiation therapy;
• Adaptive radiotherapy;
• Stereotactic radiation therapy.
One of the most common types of external-beam radiation therapy is called 3-
dimensional conformal radiation therapy (3D-CRT). Conformal radiotherapy uses
a device called a multi-leaf collimator, which allows the beam of radiation to be
shaped very precisely so that less healthy tissue is included in the therapy field. As
a result, the healthy surrounding cells and nearby structures receive a lower dose of
radiation, so the possibility of side effects is reduced.
At the same way, intensity modulated radiation therapy (IMRT) also uses multi-
leaf collimator. During the treatment, parts of the multi-leaf collimator are moved.
This enables to vary the intensity of the beam during the treatment.
In image guided radiotherapy (IGRT), 3-D scans are regularly taken during the
treatment, so imaging tools interface with the radiation delivery system through
hardware or software, and allow physicians to optimize the accuracy and precision
of the radiotherapy by adjusting the radiation beam based on the true position of
the target tumor and critical organs. This type of treatment can work well for
tumors in areas of the body that may move during treatment, for example due to
breathing [5].
Another radiotherapy technique that takes into account the body mouvement
due to the breathing is the so called respiratory gated radiation therapy. Essentially,
in this technique, the linac adapts to the patients breathing pattern, switching the
beam off when the tumor moves outside the planned treatment volume and switching
it back on when it comes back into position [6].
A new technique that compensates for changes in the location of the disease and
normal tissue during the treatment is the adaptive radiotherapy (ART). This novel
approach corrects for daily tumor and normal tissue variations through a systematic
feedback of measurements [7].
Stereotactic radiation therapy is a specialized type of external beam radiation
therapy. The term stereotactic refers to precise positioning of the target volume
within three-dimensional (3D) space. There are two types of stereotactic radiation:
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stereotactic body radiation therapy and stereotactic radiosurgery. The term body is
used to distinguish the technique from the current terminology of stereotactic radio-
surgery used for radiation treatment of central nervous system lesions. Stereotactic
positioning can be precise, and as a result, stereotactic radiotherapy commonly uses
higher doses per fraction and fewer fractions (hypofractionation) than conventional
radiation [8].
1.2 Microbeam and Minibeam Radiation Therapy
The fundamental limitation of conventional radiotherapy is the risk of long-term
damage to healthy tissue. To spare normal tissue and improve radiation treatment,
different techniques have been conceived, as already discussed in previous section.
In this context, spatially fractionated radiotherapies are included.
Spatially fractionated radiotherapy techniques such as:
• Microbeam radiation therapy (MRT);
• Minibeam radiation therapy (MBRT).
are an innovative method to spare healthy tissue.
MRT was initiated at the X17B1 superconducting wiggler beamline of National
Synchrotron Light Source (NSLS), Brookhaven National Laboratory (BNL) around
1990 [9] [10], and then later developed at the European Synchrotron Radiation Fa-
cility (ESRF, Grenoble, France) since the mid-1990s [11] [12].
MRT is a spatially fractionated radiotherapy that uses an array of microscopically
thin (25 to 100 µm width) and nearly parallel synchrotron-generated X-ray beams
separated by 100 to 200 µm center-to-center distances [9]. The high flux of syn-
chrotron light allows very high rates of dose deposition (several hundreds Gy within
less than 1 s).
The properties of microbeams that make them a good candidate for tumor therapy
are its outstanding sparing effect in healthy tissue, including the central nervous sys-
tem (CNS) [13], and their preferential damage to tumors, even when administered
from a single direction ([14], [15], [16], [17], [18], [19], [20]).
The biological basis of the healthy tissue sparing effect after MRT irradiation
is not well understood. This effect was attributed to the rapid regeneration of the
tissue’s microvessels from cells surviving outside the microbeams’ direct paths (for
microbeam arrays, this means survival in the “valley“ dose regions, i.e., the spaces
between individual microbeams) [17]. This sparing effect vanishes when the valley
dose approaches the tissue tolerance limit. Therefore, the damage threshold from
MRT seemed to depend mostly on the valley dose [15].
The preferential tumoricidal effect of microbeams is thought to be partly due to
the failure of the tumor’s microvessels to repair the damage inflicted by these beams,
which could then lead to the loss of blood perfusion and tissue necrosis ([15], [21],
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[22]). The effects might reflect major differences between the microvasculature of
normal tissues and tumors in response to radiation ([23], [24]), including the rapid
proliferation of endothelial cells in tumors which may render their microvessels more
vulnerable to microbeam damage, and the abnormal basement membrane in the
tumor’s vasculature [24].
The normal-tissue sparing effect of single-fraction microbeam arrays was estab-
lished in the brain of the adult rat and in the cerebellum of suckling rats ([15], [17],
[18], [20], [21], [25]), the CNS of duck embryos [14], the cerebellum of piglets [19],
and the skin of the mouse [22] and the rat [26].
Despite MRT potential, a main drawback of this technique is the requirement of
high photon fluxes that prevents artifacts caused by cardiosynchronous pulsations.
Such high-intensity microbeams can only be produced by a synchrotron radiation
source, which is a practical limitation for clinical implementation. Besides, mi-
crobeams require low-energy beams (<200 keV median energy), thus limiting dose
penetration to the tissue. The reason is that if the range in the tissue of the photo-
electrons and Compton electrons set in motion by incident photons is much larger
than the thickness of the microbeams, the nearly rectangular-shaped dose distribu-
tion produced by each microbeam will develop broad shoulders that fill in the dose
in the valley regions of the dose distribution (i.e., the regions between the direct
microbeams to which radiation leaks). Furthermore, the clinical implementation of
the interlaced method producing an homogeneous dose in the tumor is not possible
in MRT due to the higher technical precision required.
Therefore, following the principle of spatial fractionation, an extension of the
MRT method has been proposed by Dilmanian [27] from the National Synchrotron
Light Source (Brookhaven National Laboratory, USA): the Minibeam Radiation
Therapy.
In MBRT, the beam thickness ranges from 500 to 700 µm with a separation between
two adjacent minibeams of the same magnitude. Thicker beams used in MBRT
overcome the difficulties on the MRT implementation. Since the MBRT dose profiles
are not as vulnerable as those of MRT to beam smearing from cardiac pulsations,
high dose rates are not needed. In addition, the use of higher beam energies is
feasible in MBRT (≥ 200 keV ); this results in lower entrance doses to deposit the
same integral dose in the tumor, despite the larger penumbral doses [28] [29].
The first experiments in MBRT were performed by Dilmanian at BNL. Rat
spinal cords were irradiated with four 680 µm wide minibeams with a spacing of 4
mm. Despite the fact that some healthy tissue damage was observed, an entrance
dose of 400 Gy was tolerated in three out of four rats, as opposed to what hap-
pened in seamless beam irradiations. In addition, MBRT irradiations (680 µm wide
minibeams spaced by 1360 µm) of rat brains showed a 4-fold higher tolerance with
respect to broad beams, founding an equivalent tissue tolerance to that previously
found in MRT [27], [30].
The use of MBRT is also being explored at the ESRF [28], where studies in
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white-beam have shown a gain factor of three in the mean survival time of 9L
gliosarcoma bearing-rats with respect to controls [31]. Another study, conducted at
ESRF, demonstrates the sparing effect of minibeams on healthy tissue and shows
the feasibility of using X-ray minibeams with high doses in brain tumor radiotherapy
[32].
1.2.1 Peak-to-Valley dose ratio
In MBRT irradiation, the resulting dose profiles consist of a pattern of peaks and
valleys, with high doses along the minibeam path and low doses in the spaces be-
tween them. The minimum dose in the central region between two microbeams is
named the valley dose and the dose at the centre of the microbeam is the peak dose
(Fig. 1.1).
Figure 1.1: Example of a lateral array dose profile. Peaks and valleys regions are
pointed out.
The separation between the centers of two consecutive peaks is called center-
to-center distance (c-t-c). The ratio between the peak dose and the valley dose is
called PVDR (peak-to-valley dose ratio).
PVDR is an important dosimetric parameter in spatially fractioned techniques, since
it plays an important role in biological response. The PVDR depends on the in-
cident beam energy, beam width, c-t-c distance, irradiation field size and tissue
composition. PVDR should be as higher as possible in normal tissues and as closer
to 1 as possible in tumor to ensure an homogeneous dose at the target.
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1.3 Effectiveness of spatial fractionated radiotherapy
The smaller the field size is, the higher the tolerance of the healthy tissue: this phe-
nomenon has been known since the 60s, when Zeman and collaborators investigated
the possible hazards of heavy cosmic rays in the astronauts’s brain [33],[34],[35].
They irradiated mice brains with 22.5 MeV deuteron beams of several field sizes
and they evaluated the threshold dose to produce necrotic lesions along the first
half of the beam path (1.5 mm) within 24 days. The reconstruction of the results is
represented in figure 1.2. The tolerance doses remain almost constant for field sizes
Figure 1.2: Tolerance doses (in Gy) of mice brains to irradiation with 22.5 MeV
deuteron beams of several widths (mm). There is an inverse relationship between
radiosensitivity and volume of tissue exposed for small volumes. This is known as
the dose-volume effect [33].
larger than approximately 0.1 mm; below this value, the tolerance dose increases
drastically.
Figure 1.3 shows histology images of mice brains irradiated with 22.5 MeV
deuteron beams. The image on the left-hand side refers to an irradiation with a
beam diameter of 1 mm and entrance dose of 280 Gy, while the right-hand side
image shows the effect of a microbeam 25 µm diameter and a much higher dose of
4000 Gy. The paths of the beams are shown as dotted lines. For the irradiation with
the microbeam the tissue is well preserved despite the high dose. For the millimetric
irradiation beam, 240 Gy is enough to completely destroy the tissue.
This result clearly indicate that there is an inverse relationship for small volumes
between radiosensitivity and volume of tissue exposed.
The dose-volume effect might be explained by the stem cell depletion hypothesis
[36]: for each organ, there is a critical volume that can be repopulated by a single
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Figure 1.3: Histology images of mice brains illustrating the dose-volume effect. On
the left, complete tissue destruction is observed after irradiation with a 22.5 MeV
deuteron beam of 1 mm of diameter and an entrance dose of 280 Gy. On the right,
the tissue is well preserved after irradiation with a 25 µm wide beam and an entrance
dose of 4000 Gy [34].
survival stem cell that migrates from the nearby tissue to recover the tissue damaged
by the radiation. Thus, the combination of submillimetric field sizes and spatial
fractionation of the dose provides a further gain in tissue sparing due to the biological
repair of the microscopic lesions by the minimally irradiated contiguous cells.
So the possible improvement of spatially fractionated radiotherapy, is the su-
perior normal tissue tolerances, allowing the use of higher and potentially curative
doses.
1.4 Hadrontherapy
Other than x-rays radiation therapy techniques, other methods are available or in
development, such as hadrontherapy which is an advanced external RT technique
that uses charged particles such as protons, alphas, C, O, etc.
By contrast with X-rays or γ-rays, which are absorbed by the body and show
an exponential decrease in the radiation dose with increasing tissue depth, charged
particles instead are characterized by a relatively low dose at the shallow depths,
a peak near the end of the range, and then a rapid fall-off (Fig.1.4). The peak
occurs immediately before the particles come to rest and is called the Bragg peak,
for William Henry Bragg who discovered it in 1903.
The idea is to deliver a high dose of ionizing radiation to a deep seated tumor
while not exceeding the tolerance dose of the intervening normal tissues, and no
dose will be given to normal tissues beyond the tumor.
Wilson was the first to point out the advantageous dose distributions of protons
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Figure 1.4: Comparison of the depth dose relationships for X-rays and high-energy
charged particles [37].
and their potential for cancer therapy.
Since the Bragg peak for particles of a given energy is very narrow, beams of
different energies have to be superimposed to produce a spread-out Bragg peak
(SOBP) that covers the whole tumor (Fig.1.5).
A SOBP can be produced in two possible ways: a beam of particles with a fixed
energy can be attenuated with range shifters of variable thickness, which produces
Bragg curves that peak at different depths along the tumors (passive modulation).
Alternatively, the energy of the particle beam can be varied in the accelerator, and
in this case no passive attenuators are needed (active modulation).
Always Wilson proposed for first, the use of range modulation wheels for pro-
ducing spread-out Bragg peaks that cover larger targets that can be treated with
pristine Bragg peaks.
The first proton treatment of human patients was carried out by Tobias, Lawrence
and others on the LBL cyclotron in the late 1950s.
In 1958, Larson and Leksel reported the first use of range modulation to form a
SOBP and beam scanning to produce large treatment fields in the lateral dimension.
From the late 1960s until 1980, there were significant efforts in the development
of proton therapy at several physics research facilities around the world. Proton
therapy programs were initiated in Russia and in Japan. Between 1980 and 2000,
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Figure 1.5: Example of SOBP [37].
there was a flurry of activity in proton therapy around the world, with patients
treatment starting in England, France, South Africa, Switzerland, Germany, Japan
and Russia.
In 1975, Cornelius A. Tobias proposed that particles heavier than protons could
give additional advantages. In fact, heavy ions have reduced lateral scattering com-
pared with protons, which leads to a further improvement in the dose distribution
to the target area. The main potential advantages of heavy ions, however, are in
their radiobiological effects on tissues. The relative biological effectiveness (RBE;
that is, the ratio of X-ray and particle dose producing the same biological effect) of
charged particles is increased by increasing the particle ionization density, or linear
energy transfer (LET). The LET depends on the charge and velocity of the ion: fast
moving, light ions have low LET, and their biological effectiveness is close to that
of X-rays; slow, heavy ions have high LET, and are more effective than X-rays for
killing cells, as well as for other end points, such as causing mutations.
Most of the clinical experience with ions heavier than protons involves carbon,
because this particle has an RBE of about 1 in the entrance channel and as high as 3-
4 in the Bragg peak region. Ions heavier than carbon are difficult to use for therapy,
first because the nuclear fragmentation of the projectile unfavorably modifies the
shape of the Bragg curves, and second because LET is already high in the entrance
channel. Oxygen can be used in special cases; for example, very hypoxic tumors.
On the other hand, ions with mass between those of protons and carbon (from 4He
to 10B) could also have applications in therapy. The physical and radiobiological
basis of the action of energetic charged particles suggest that the use of protons can
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represent a technical improvement for conformal therapy, and heavy ions a potential
breakthrough for the treatment of radiotherapy-resistant cancers such as renal-cell
carcinoma, melanoma and glioblastoma [37].
1.4.1 Hadrontherapy facilities in Europe
Hadrontherapy is today part of the medical business landscape, several companies
are focusing their work, not only in protontherapy centers, but also on carbon ther-
apy facilities.
As already explained, the concentration of energy deposition of ions in a local-
ized Bragg peak gives a better ballistic precision compared to photons, so a better
preservation of the healthy tissues and organ at risk in the tumor vicinity.
Concerning the ballistic precision, carbon ions have the disadvantage of dose deposi-
tion after the Bragg peak due to the ion fragmentation. Nevertheless, this drawback
is largely compensated by a much lower radial diffraction, a diffraction which pe-
nalizes protons for the treatment of deep-seated tumors.
The decisive advantage of ions compared to photons and protons comes from their
higher LET and RBE, that is why a major attention is now focused on the devel-
opment of carbon therapy.
In this paragraph, some of the hadrontherapy facilities in Europe are presented [38].
GSI, Germany : with HIMAC in Japan, GSI is the place where a decisive pi-
oneer work has been done for carbon therapy. First of all, here, has been done
the research works on the RBE of the ions and the links between RBE and DNA
damages, repairing and non-repairing cells. The ”Local-Effect-Model” (cell survival)
has been built and verified making in-vitro and in-vivo experiments. Finally, the
RBE modelling has been validated and a Treatment Planning System (TPS) has
been constructed. GSI makes also decisive technical developments to improve the
quality of the treatments. The most famous is the raster scanning (spot-scanning)
technique which allows a nearly perfect dose deposition in the tumor with an opti-
mal preservation of the surrounding tissues.
HIT Heidelberg, Germany : the work done at GSI has lead to the construction
of a dedicated heavy ion therapy center at Heidelberg. The accelerator started to
work in 2007. This facility is equipped with 3 treatment areas, and it can work with
p, He, C, O ions in a range energy 50-430 MeV/nucleon.
CNAO, Pavia, Italy : the realization of the Italian National Center for Oncolog-
ical Hadrontherapy (CNAO) started in 2002. The basic design of the accelerator
and beam lines comes from the Proton-Ion Medical Machine Study (PIMMS) done
at CERN. This carbon facility is equipped with 3 treatment rooms and a room for
QA and experimental researches.
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1.4.2 Carbon therapy facilities around the world
Carbon therapy facilities in operation:
Country Energy (MeV) Start Tot. patients at date
HIMAC, Chiba Japan 800/u 1994 6569 Dec-11
HIBMC, Hyogo Japan 320/u 2002 788 Dec-11
HIT, Heidelberg Germany 430/u 2009 980 Dec-12
GHMC, Gunma Japan 400/u 2010 271 Dec-11
IMP-CAS, Lanzhou China 400/u 2006 159 Dec-11
CNAO, Pavia Italy 430/u 2011 0 Nov-12
Carbon therapy facilities in a planning stage or under construction:
Country Energy (MeV) No. rooms Start planned
Med-AUSTRON, Wiener Neustadt Austria 430/u 3 2015
Fudan University, Shanghai China 430/u 3 2014
PTC, Marburg Germany 430/u 4 2012?
All those data, are published on the Particle Therapy Co-Operative Group
(PTCOG) website:
http://ptcog.web.psi.ch/
1.5 Combination of spatially fractionated techniques and
hadrontherapy
The aim of this work is to study the possible feasibility of an heavy ion treatment
with arrays of minibeams.
The new technique will take advantages on the sparing of normal tissue from
the spatially fractionated method and from the better ballistic of heavy ion therapy,
and a gain, from the radiobiological point of view, will be add thanks to the RBE
characteristic of heavy ions.
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Radiobiology is a branch of science concerned with the action of ionizing radi-
ation on biological tissues and living organisms. Knowledge of the radiobiology of
normal tissues and tumors is a core prerequisite for understanding the main differ-
ence between x-ray radiation therapy and hadrontherapy.
The biological effects of irradiation are the end product of a long series of phe-
nomena which are set in motion by the passage of radiation through the medium.
The initial events are ionizations and excitations of atoms and molecules of the
medium along the tracks of the ionizing particles. These physical perturbations
lead to physico-chemical reactions, then chemical reactions and finally the biologi-
cal effect [39].
Ionizing radiation may be divided into directly and indirectly ionizing for the
understanding of biological effects. Most of the particulate types of radiation are
directly ionizing as they can directly break up the atomic structure of the absorb-
ing medium through which they pass producing chemical and biological damage
to molecules. In contrast, electromagnetic radiations, namely, X and γ rays, are
indirectly ionizing because they do not produce chemical and biological damage
themselves but produce secondary electrons after energy absorption in the material.
The biological effects of radiation result principally from damage to DNA, which
is the critical target. If any form of radiation is absorbed in biological material, there
is a possibility that it will interact directly with the critical targets in the cells. The
atoms of the target itself may be ionized or excited, thus initiating the chain of events
that leads to a biologic change. This is called direct action of radiation and it is the
dominant process if radiations when high linear energy transfer (LET) is considered.
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Alternatively, the radiation may interact with other atoms or molecules in the cell
(particularly water) to produce free radicals that are able to diffuse far enough to
reach and damage the critical targets. This is called indirect action of radiation [40].
2.1 Linear energy transfer
When ionizing radiations traverse through matter, they lose energy gradually through
various interaction processes along the length of their path. For a particular ab-
sorber, the rate of loss of energy depends on the energy and type of radiation as
well as the density of the material.
The density of energy deposition in a material is called the Linear Energy Transfer
(LET) of the radiation. It is defined as the average energy deposited per unit length
of track of radiation and the unit is keV/µm.
LET essentially indicates the quality of different types of radiation and is impor-
tant because the biological effect of a radiation (its relative biological effectiveness,
RBE) depends on its average LET.
Radiations are categorized into low and high LET, with charged particles radia-
tions usually being high LET radiations (because of their greater energy deposition
along the track) whereas X and γ rays are low LET radiations due to their sparse
ionizations. As the charged particle deposits energy in a tissue, it slows down. Due
to this fact, the LET varies along the path of these particles, while the energy trans-
fer rate (−dE/dX, loss of energy per unit distance) increases. This is shown by a
peak of energy deposition at the end of the track (the Bragg peak).
Energy loss events are essentially randomly distributed along the track of the
photon or charged particle. For low LET radiations the energy deposition events
along the track of the photon are sparse relative to the dimensions of biomolecules
such as DNA, with the result that photons may pass through such a molecule without
depositing any energy. For such radiations the amount of energy deposited in a
region of the track similar in dimensions to biological molecules also varies widely
from a few eV up to 100s of eV . For high LET radiation the energy loss events are
much more closely spaced and a significant amount of energy will be deposited along
all parts of the track similar in dimension to biomolecules. Typical LET values for
various radiations are listed in table 2.1.
2.2 Chemical interactions
The physical interactions of ionizing radiation lead to loss of energy of radiation
and production of ionization and excitation of atoms and molecules which may con-
vert into free radicals in pico to femto seconds after physical interaction with atoms
(10−13 to −15 s).
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Typical LET values of ionizing radiation
Radiation LET keV/µm
Co-60 γ rays 0.2
250 kVp X-rays 2.0
10 MeV protons 4.7
150 MeV protons 0.5
14 MeV neutrons 12
2.5 MeV α particles 166
2 GeV Fe ions 1000
Table 2.1: Hall and Giaccia, [40]
Hereafter, it is schematized the process conducting from the physical interaction
to the biological effects:
Ionizing radiation
↓
Fast electron
↓
Ion radical
↓
Free radical
↓
Chemical changes from the breakage of bonds
↓
Biological effects
A free radical is an atom or molecule carrying an unpaired orbital electron in
the outer shell.
In an atom or molecule with an even number of electrons, spins are paired: this
state is associated with a high degree of chemical stability. In an atom or molecule
with an odd number of electrons, there is one electron in the outer orbit for which
there is no other electron with an opposing spin; this is an unpaired electron. This
state is associated with a high degree of chemical reactivity.
Radiation interactions that produce biologic changes are classified as either direct
or indirect. The change takes place by direct action if a biological macromolecule
such as DNA, RNA, or protein becomes ionized or excited by an ionizing particle
or photon passing through or near it. Indirect effects are the result of radiation
interactions within the medium (e.g. citoplasm) which create reactive chemical
species that in turn interact with the target molecule (see picture 2.1).
Because 70% to 85% of the mass of living systems is composed of water, the vast
majority of radiation-induced damage is mediated through indirect action on water
molecules.
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Figure 2.1: Direct and indirect actions [41]
The absorption of radiation by a water molecule results in an ion pair (H2O+, H2O−).
The H2O+ ion is produced by the ionization of H2O, whereas the H2O− ion is pro-
duced via capture of a free electron by a water molecule.
These ions are very unstable; each dissociates to form another ion and a free radical:
H2O
+ → H+ +OH•
H2O
− → H •+OH−
The H+ and OH− ions do not typically produce significant biologic damage
because of their extremely short lifetimes (≈ 10−10sec) and their tendency to re-
combine to form water.
Free radicals are extremely reactive chemical species that can undergo a variety of
chemical reactions. Free radicals can combine with other free radicals to form non-
reactive chemical species such as water (e.g., H •+OH• = H2O), in which case no
biologic damage occurs, or with each other to form other molecules such as hydrogen
peroxide (e.g., OH •+OH• = H2O2), which are highly toxic to the cell.
Free radicals can act as strong oxidizing or reducing agents by combining directly
with macromolecules. The damaging effect of free radicals is enhanced by the pres-
ence of oxygen. Oxygen stabilizes free radicals and reduces the probability of free
radical recombination to form water. Oxygen combines with the hydrogen radical
to form the highly reactive hydroperoxyl radical (e.g., H •+O2 = HO2•).
Although their lifetimes are limited (less than 10−5 sec), free radicals can diffuse
in the cell, producing damage at locations remote from their origin. Free radicals
may inactivate cellular mechanisms directly or via damage to genetic material (DNA
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and RNA), and they are believed to be the primary cause of biological damage from
low LET radiation.
2.3 Radiation lesions in DNA
Cells contain numerous macromolecules, only some of which are essential for cell
survival. If a key molecule, for which the cell has not replacement (e.g. DNA), is
damaged or destroyed, the result may be cell death. There is considerable evidence
that damage to DNA is the primary cause of radiation-induced cell death.
Radiation causes a wide range of lesions in DNA such as single-strand breaks,
double-strand breaks (in which both strands of the double helix break simultaneously
at approximately the same nucleotide pair), base loss, or base changes (see figure
2.2).
Figure 2.2: Examples of DNA mutations. [41]
The number of DNA lesions generated by irradiation is large, but the number
giving rise to cell kill is extremely small [42]. The numbers of lesions induced in the
DNA of a cell by a dose of 1-2 Gy from photon radiation are approximately:
Double-strand breaks play a critical role in cell killing, and there are experimental
data showing initially-produced double-strand breaks correlate with radiosensitivity
and survival at low dose, and unrepaired or mis-repaired double-strand breaks to
correlate with survival after higher doses. Increasing evidence suggests the impor-
tance of complex double-strand breaks lesions after high LET irradiation.
The single-strand breaks are more easily repaired than double-strand breaks and
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Events per 1-2 Gy dose
Ionization ≈ 100000/cell
Base damage > 1000/cell
Single strand breaks ≈ 1000/cell
Double strand breaks ≈ 40/cell
Cell deaths ≈ 0.63/cell
Table 2.2: Frequency of DNA damage from photon radiation, [42]
are more likely to result from the sparse ionization pattern that is characteristic of
low-LET radiation.
Knowledge of radiation track structure has been used to explain the wide varia-
tion and wide distribution of lesions in DNA. The importance of clusters of energy
deposition events (ionizations and excitations) at track termini of secondary elec-
trons resulting in multiple closely-spaced lesions (multiply damaged sites) within a
range of 20 nm, has been recognized as crucial for cell killing and for the ability of
cells to repair such lesions.
Different repair pathways are used to repair DNA damage, depending on the
stage of the cell cycle. If the damage is not repaired before DNA synthesis, the
lesion may be transmitted during mitosis and meiosis. Chromosomal damage that
occurs before DNA replication is referred to as chromosome aberrations, whereas
that occurring after DNA synthesis is called chromatid aberrations. Unlike chromo-
somal aberrations, only one of the daughter cells will be affected if only one of the
chromatids of a pair is damaged.
Aberrant chromosomes arise when broken ends rejoin with other broken ends
to generate rings, dicentrics, translocations and other chromosome aberrations. Di-
centric chromosome aberrations arise post replication from the joining of 2 broken
chromatids in different chromosomes and can be used as a marker for radiation ex-
posure. Acentric fragments and dicentrics are unstable aberrations and may not
survive past the next mitosis, implicating loss of genetic material which may signal
death in diploid cells.
2.4 Cell cycle and cell death
Cells are the unit that make up tissues. They contain inorganic compounds (water
and minerals) as well as organic compounds (proteins, carbohydrates, nucleic acids
and lipids).
The two main constituents of a cell are the cytoplasm, which supports all metabolic
functions within the cell, and the nucleus, which contains the genetic information
(DNA).
The cell proliferation cycle is divided in four periods: G1, S, G2, M.
S is the period of DNA synthesis and M stands for mitosis, where division takes
place. The S and M portions of the cell cycle are separated by the two periods
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G1 and G2 when, respectively, DNA has not yet been synthetized or has been
synthetized but other metabolic processes are taking place.
Figure 2.3: Schematic representation of the cell cycle [40].
In general, cells are most radiosensitive in the M and G2 phases, and most
resistant in the late S phase [40].
The cell cycle time of malignant cells is shorter than that of some normal tissue
cells, but during regeneration after injury normal cells can proliferate faster. Cell
death of non-proliferating cells is defined as the loss of a specific function, while
for stem cells and other cells capable of many divisions it is defined as the loss of
reproductive integrity. A surviving cell that maintains its reproductive integrity and
proliferates almost indefinitely is said to be clonogenic.
Irradiation of a cell will result in one of the following nine possible outcomes:
• no effect;
• division delay: the cell is delayed from going through division;
• apoptosis: the cell dies before it can divide or afterwards by fragmentation
into smaller bodies, which are taken up by neighbouring cells;
• reproductive failure: the cell dies when attempting the first or subsequent
mitosis;
• genomic instability: there is a delayed form of reproductive failure as a result
of induced genomic instability;
• mutation: the cell survives but contains a mutation;
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• transformation: the cell survives but the mutation leads to a transformed
phenotype and possibly carcinogenesis;
• bystander effects: an irradiated cell can send signals to neighbouring unirra-
diated cells and induce genetic damage in them;
• adaptive response: the irradiated cell is stimulated to react and become more
resistant to subsequent irradiation.
The timescale involved between the breakage of chemical bonds and the biologi-
cal effect may be hours to years, depending on the type of damage. If cell kill is the
result, it may happen in hours to days, when the damaged cell attempts to divide
(early effect of radiation); this can result in early tissue reactions if many cells are
killed. If the damage is oncogenic, then its expression may be delayed for years (late
effect of radiation) [4].
In general, the radiation sensitivity of a tissue is proportional to the rate of
proliferation of its cells and inversely proportional to the degree of cell differentiation.
For example, the following tissues and organs are listed from most radiosensitive
to least radiosensitive:
Most sensitive: blood-forming organs
reproductive organs
skin
bone and teeth
muscles
Least sensitive: nervous system
Factors that make cells less radiosensitive are: removal of oxygen to create a
hypoxic state, the addition of chemical radical scavengers, the use of low dose rates
or multifractionated irradiation, and cells synchronized in the late S phase of the
cell cycle [4].
2.5 Cell survival curves and therapeutic index
A cell survival curve depicts the relationship between the fraction of cells retaining
their reproductive integrity and the absorbed dose.
Cell survival as a function of radiation dose is graphically depicted on a logarithmic
scale, and is plotted on the y-axis against dose on the x-axis. Cell surviving fractions
are determined with in vitro or in vivo techniques. Examples of survival curves for
cells irradiated by densely and sparsely ionizing radiation beams are shown in figure
2.4.
The type of radiation influences the shape of the cell survival curve. Irradiation
of cells with high-LET radiation produces linear survival curves on the log-linear
plot. For low LET radiation, however, the curves show an initial slope followed by
a shoulder region and then become nearly straight at higher doses.
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Figure 2.4: Typical cell survival curves for densely ionizing radiation (high LET)
and sparsely ionizing radiation (low LET) in the linear quadratic model [4].
Several mathematic methods have been developed to define the shape of cell
survival curves; nowadays, the most often used is the linear quadratic method:
S(D) = e−αD−βD
2
where:
S(D) is the fraction of cells surviving a dose D;
α is a constant describing the initial slope of the cell survival curve;
β is a smaller constant describing the quadratic component of cell killing.
The ratio α/β gives the dose at which the linear and quadratic components of cell
killing are equal.
It is also possible to define a dose response curve as a plot of a biological effect
observed versus the dose given: with increasing radiation dose, radiation effects may
increase in severity, in frequency, or both. Such dose response curves have a sigmoid
shape, with the incidence tending to zero as dose tends to zero and the incidence
tending to 100% at very large doses. This applies to both tumor control and normal
tissue complications (Fig. 2.5).
The effects of radiation on tissue as a function of dose are measured with assays
and the measurement results are given in the form of cell survival curves or dose
response curves.
The ratio of the tumor response for a fixed level of normal tissue damage is called
therapeutic index or therapeutic ratio. In the hypothetical example in figure 2.5,
there is a favorable therapeutic index, because a 30% probability of tumor control
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Figure 2.5: Example of response curves. Tumor control probability and normal tissue
complications are plotted as a function of dose. What is illustrated is a favorable
situation where the tumor is more radiosensitive than the normal tissue [40].
is possible for a 5% incidence of complications. The two sigmoid curves depicted on
that figure are, one for the tumor control probability (TCP) and the other for the
normal tissue complication probability (NTCP). The optimum choice of radiation
dose delivery technique in the treatment of a given tumor is such that maximize
the TCP and simultaneously minimizes the NTCP. For a typical good radiotherapy
treatment, TCP≥ 0.5 and NTCP≤ 0.05. So the therapeutic index can also be
defined as the ratio of the TCP and NTCP at a specified level of response (usually
0.05) for normal tissue.
The therapeutic index varies with many factors, such as the dose rate and LET,
the presence of radiosensitizers or radioprotectors, the design of the treatment plan
and the precision of implementation of the treatment plan. However, it is imperative
that the average doses to normal tissues be kept lower than the doses to tumors in
order to minimize treatment complications and optimize treatment outcomes. In
modern radiotherapy this is achieved through sophisticated 3D treatment planning
and dose delivery.
2.6 Relative biological effectiveness
Although all ionizing radiations are capable of producing the same types of biologi-
cal effects, the magnitude of the effect per unit dose differs. Equal doses of radiation
of different LETs do not produce the same biologic response. To evaluate the ef-
fectiveness of different types of radiations and their associated LETs, experiments
are performed that compare the dose of the test radiation required to produce the
same specific biologic response produced by a particular dose of a reference radiation
(typically x-rays produced by a potential of 250 kVp).
The RBE relates the effectiveness of the test radiation to the reference radiation.
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For identical exposure conditions, it is defined as follows:
RBE =
Dose of 250-kVp x-rays required to produce effect X
Dose of test radiation required to produce effect X
RBE depends on the following:
• LET;
• radiation dose;
• number of dose fractions;
• dose rate;
• biological system or end point.
So, as stated before, radiation quality includes the type of radiation and its
energy, whether electromagnetic or particulate, and whether charged or uncharged.
RBE depends on the dose level and the number of dose fractions (or, alterna-
tively, the dose per fraction) because in general, the shape of the dose-response
relationship varies for radiations that differ substantially in their LET.
RBE can vary with the dose rate because the slope of the dose-response curve
for sparsely ionizing radiations, such as x- or γ-rays, varies critically with a changing
dose rate. In contrast, the biologic response to densely ionizing radiation depends
little on the rate at which the radiation is delivered.
The biologic system or the end point that is chosen has a marked influence on the
RBE values obtained. In general, RBE values are high for tissues that accumulate
and repair a great deal of sublethal damage and low for those that do not.
2.6.1 RBE as function of LET
As the LET increases, the RBE increases slowly at first and then more rapidly as the
LET increases beyond 10 keV/µm. Between 10 and 100 keV/µm, the RBE increases
rapidly with increasing LET and in fact reaches a maximum at about 100 keV/µm.
Beyond this value for the LET, the RBE again falls to lower values.
Radiation with a LET of about 100keV/µm is optimal in terms of producing a
biologic effect. At this density of ionization, the average separation between ionizing
events coincides with the diameter of the DNA double helix (≈ 2nm). Radiation
with this density of ionization has the highest probability of causing a double-strand
break by the passage of a single charged particle.
In the case of x-rays, which are more sparsely ionizing, the probability of a single
track causing a double-strand break is low, and in general more than one track is
required. As a consequence, x-rays have a low biologic effectiveness.
At the other extreme, much more densely ionizing radiations (with a LET of 200keV/µm)
readily produce double-strand breaks, but energy is wasted because the ionizing
events are too close together. Because RBE is the ratio of doses producing equal bi-
ologic effect, this more densely ionizing radiation has a lower RBE than the optimal
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LET radiation. The more densely ionizing radiation is just as effective per track,
but less effective per unit dose.
Figure 2.6: The most biologically effective LET is that at which there is a coincidence
between the diameter of the DNA helix and the average separation of ionizing events.
[40]
2.7 The oxygen effect and radiosensitivity
The presence or absence of oxygen within a cell influences the biological effect of
ionizing radiation: the larger the cell oxygenation, the larger is the biological effect
of ionizing radiation especially for low LET radiations [4]. As shown in figure 2.8,
the effect is quite dramatic for low LET (sparsely ionizing) radiations, while for high
LET (densely ionizing) radiations it is much less pronounced.
The ratio of doses without and with oxygen (hypoxic versus well oxygenated
cells) to produce the same biological effect is called the oxygen enhancement ratio
(OER):
OER =
Dose to produce a given effect without oxygen
Dose to produce the same effect with oxygen
The OER decreases as the LET increases and approaches as shown in figure 2.9.
Cells at the periphery of tumour cords growing around blood vessels become
chronically hypoxic because of the consumption of most of the oxygen near the
blood vessel. The transient closing of blood vessels can also make the whole tumour
cord hypoxic for a few minutes at a time. Reoxygenation is the process by which
cells that are hypoxic become oxygenated after irradiation, through the killing and
removal of oxic radiosensitive cells from the tumour.
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Figure 2.7: Schematic representation of tracks of sparsely and densely ionizing ra-
diations compared with relevant biological targets (chromatin fiber, nucleosomes and
DNA double helix). [43]
Figure 2.8: Typical cell surviving fractions for X-rays, neutrons and α particles:
dashed curves are for well oxygenated cells, solid curves for hypoxic cells. [4]
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Figure 2.9: OER plotted against LET. The vertical dashed line separates the low
LET region, where LET < 10keV/µm, from the high LET region, where LET >
10keV/µm. [4]
2.8 Radiobiological motivation for hadrontherapy
The particle or hadron beams deployed in radiotherapy (protons, neutrons and he-
lium, carbon, oxygen and neon ions) have a physical and radiobiological characteris-
tics which differ from those of conventional radiotherapy beams (photons) and which
offer a number of theoretical advantages over conventional radiotherapy. The main
potential advantages of heavy ions are in their radiobiological effects on tissues. The
RBE of charged particles is increased by increasing the particle ionization density
(LET).
The LET depends on the charge and velocity of the ion: fast moving, light ions
have low LET, and their biological effectiveness is close to that of X-rays; slow,
heavy ions have high LET, and are more effective than X-rays for killing cells, as
well as for other end points, such as causing mutations.
As an example, carbon ions at an energy of 300 MeV per nucleon have a range in
water around 20 cm, and can be used to treat deep tumors. The LET of such ions is
low (around 10 keV/µm) in the entrance channel, where normal tissue is exposed,
and high (around 50-80 keV/µm) in the Bragg peak region, where the tumor is
located. As a result, the biological effects of treatment with these ions in normal
tissue are comparable to those seen with X-rays (and, therefore, normal tissue com-
plications are similar to those expected in conventional treatment); however, cell
killing is enhanced in the tumor region.
High LET (densely ionizing) radiation has several other radiobiological advan-
tages compared to X-rays. Cells are well known to have increased sensitivity to
X-rays in the presence of oxygen, but the oxygen enhancement ratio is reduced at
high LET values, with the result that hypoxic tumors have increased sensitivity to
heavy ions. The cell-cycle dependence of cell killing, as well as the cell-sparing effect
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of fractionation, are also reduced in the Bragg peak region, which further enhances
the effectiveness of particle therapy in the tumor compared to the normal tissue.
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On this chapter, the Monte Carlo code GATE, used for the simulations, has
been described in particular focusing on the phantom, the source and the readout
parameters.
The physics list has also an extremely significant role in the simulations. So the
physics for hadrons interactions in matter will be briefly described and so its imple-
mentation in the code.
3.1 The Monte Carlo method
The name “Monte Carlo” was coined in the 1940s by scientists working on the nuclear
weapon project in Los Alamos, to designate a class of numerical methods based on
the use of random numbers.
The Monte Carlo method is a statistical approach of deriving a macroscopic solution
to a problem by the use of random numbers. It involves the random sampling of
probability distribution functions that describe the problem of interest. Provided
that the algorithm is accurate and the physical system is well modeled, repeated
sampling of the distributions will converge to the correct solution.
Monte Carlo methods usually follow different approaches, depending on the par-
ticular field of application. However, these approaches tend to follow a particular
scheme: define a domain of possible inputs, generate inputs randomly from the
domain using a certain specified probability distribution, perform a deterministic
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computation using the inputs and aggregate the results of the individual computa-
tions into the final result. Thus, the reliance computation is sensitively dependent
on the goodness of the random numbers, which are required in large amounts to
achieve good statistics. This requirement led to the necessity of using methods
which in some a way are able to “create“ long chain of random numbers, giving rise
to the development of the so called pseudorandom1 numbers generators.
Nowadays, Monte Carlo methods are widely used to solve complex physical and
mathematical problems ([51]), they are especially useful to study systems with a
large number of coupled degrees of freedom, such as fluids, disordered materials,
strongly coupled solids, and cells.
In the Monte Carlo simulation of radiation transport, particles travel in discrete
steps and undergo various types of interactions along the way. The history of a
particle is viewed as a random sequence of free flights that end with an interac-
tion event where the particle changes its direction of movement, loses energy and,
occasionally, produces secondary particles. The step length and the type of interac-
tion are sampled from cross section data. Sampling of the appropriate differential
cross sections, random histories can be generated and so energy and direction of the
resultant particles can be determined.
The integral parts of the code include: the cross section data of the processes to
be simulated, the particle transport algorithms, the specifications of the geometries
and quantities to be scored, as well as the analysis of the simulation.
3.2 The GATE simulation toolkit
Monte Carlo simulation is a essential tool in nuclear medicine. Accurate and ver-
satile simulation codes such as GEANT3/4, EGS4, MCNP/MCNPX, PENELOPE,
FLUKA, they all include well-validated physics models, geometry modeling tools,
and efficient visualization utilities. However these packages are quite complex and
necessitate a steep learning curve.
GATE is an advanced opensource software developed by the international Open-
GATE collaboration and dedicated to numerical simulations in medical imaging and
radiotherapy. It currently supports simulations of Emission Tomography (Positron
Emission Tomography - PET and Single Photon Emission Computed Tomography
- SPECT), Computed Tomography (CT) and Radiotherapy experiments. Using an
easy-to-learn macro mechanism to configurate simple or highly sophisticated exper-
imental settings, GATE now plays a key role in the design of new medical imaging
devices, in the optimization of acquisition protocols and in the development and
1A pseudorandom number generator is an algorithm for generating a sequence of numbers that
approximates the properties of random numbers. The sequence is not truly random in the sense
that it is completely determined by an initial state, usually named seed. When Monte Carlo
simulations are exploited to produce a unique result by splitting the process in several tasks, the
use of different seeds is mandatory.
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assessment of image reconstruction algorithms and correction techniques. It can
also be used for dose calculation in radiotherapy experiments.
Gate is a GEANT4 application that encapsulates the GEANT4 libraries in order
to achieve a modular, versatile, scripted simulation toolkit adapted to the field of
nuclear medicine.
Here, a brief description of the code is presented. A general simulation architec-
ture for dosimetry and radiotherapy applications follows:
• define the source;
• define the phantom geometry;
• specify the output;
• setting up the physics processes;
and then initialize the simulation.
3.2.1 Source
A source in GATE is defined by its:
• particle type (e.g. radionuclide, gamma, positrons, ions, etc);
• position (volume);
• direction (solid angle);
• energy (spectrum).
A source is represented by a volume in which the particles are emitted. The
type of particle can be choose from a list of simple particles (e−, e+, γ, etc) or a ion
source can be simulated defining its atomic number, atomic weight, ionic charge in
units of energy and its excitation energy in keV .
Different types of source distribution can be defined: volume, point, beam, plane
or surface, as well as its placement.
The angular distribution of the emission can also be defined. By default, a full
span of 0-180 degrees for the polar angle and 0-360 degrees for the azimuthal angle
are defined.
At last, the energy distribution can be expressed using a pre-defined spectrum
or by using built-in distributions.
3.2.2 Phantom geometry
The definition of a geometry is a key step in designing a simulation. Particles are
then tracked through the components of the geometry.
When a volume is created with GATE a shape has to be assigned to it. Different
volume shapes are available, namely: box, sphere, cylinder, cone, hexagon, general
34 Chapter 3. Materials and Methods
or extruded trapezoid, wedge and elliptical tube. After creating a volume with a
shape, its dimensions are the default dimensions associated with that shape. These
default dimensions can be modified.
A material must be associated with each volume. The default material assigned
to a new volume is air. The primary method for defining the properties of the
materials used in Gate is by a materials database. This file holds all the information
required for Gate to assign the nuclear properties from the Geant4 data sets, and is
easily modified by the user. The material database contains two Geant4 structures
called elements and materials that are used to define the physical properties of the
atoms, molecules, and compounds. In contrast with Geant4, Gate does not use
isotopic abundances. Elements are the building blocks of all the materials used in
Gate simulations. Elements in Gate are defined as in a periodic table. Gate stores
the elements name, symbol, atomic number, and molar mass. In Gate, materials
are defined as combinations of elements, and are an important parameter that Gate
uses for all of the particle interactions that take place during a simulation. These
combinations of elements require defining four additional parameters. These are the
material’s name, density, constituent element(s), and their individual abundances.
In GATE, the parametrized volume method is available for voxelized phantoms.
The parametrized volumes method offers several advantages such as: voxel that can
be varied in size, shape and material, voxel not entirely filling the envelope, and
visualization attributes.
In GATE, a compression algorithm is also implemented, in order to generate a
compressed phantom where voxel size is variable; all adjacent voxels of the same
material are fused together to form the largest possible rectangular voxel. A com-
pressed phantom uses less memory and also less CPU.
3.2.3 Readout parameters
Actors are tools which allow to interact with the simulation. There are different
types of actors which collect different types of information, such as energy deposit,
number of particles created in a given volume, etc.
Some actors, such as the dose actor, can store some information into a 3D
rectangular image (or matrix) according to the spatial position of the hit. User can
specify the resolution of the 3D matrix (in this case, the size is equal to the size of
the bounding box of the attached volume). Alternatively, user can specify the size
to allow larger of smaller matrices.
3.2.4 Physics setup
There is a wide set of physics models to handle the interactions of particles with
matter across a very wide energy range. Physics models cover the physics of photons,
electrons, muons, hadrons and ions.
Currently, the maximum energy used in a medical application is 5 GeV per
particle. Thus, simulation of medical applications requires electromagnetic and
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hadronic processes below 10 GeV.
Each process have a model which generates the final state and a cross-section
which represents the probability of interaction (the cross-section is sometimes called
dataset).
In GATE is possible to define a physics list specifying all the particles, physics
processes and cut-off parameters.
3.3 Physical processes of interest in this work
Charged particles interact with a transversing medium through a large number of
collisions with the atoms of the medium. These collisions can be either elastic,
in which the involved particle momenta are conserved, or inelastic, where part of
the momenta and energy is converted. For heavy particles, the effect of the elastic
collisions is mainly a small deflection of the particle trajectory inducing a range and
a lateral spreading, and the main physical process involved is the inelastic collision
of nuclei on the electrons of atoms present in the target matter.
In that process, the projectile of kinetic energy Ee, looses an energy δE = ee + I
where ee is the energy of the out-coming electron and I the ionization potential of
that electron.
The impinging particles transfer most of their energy via secondary electron
production, so the emitted electrons, or δ−rays, forms the core of the track around
the particle trajectory.
For heavy ions, the most of the primary energy is deposited by collisions of
primary, secondary, and later generations of electrons with target molecules. The
rest of the energy is consumed in nuclear processes, like nuclear collisions and nuclear
fragmentation, and excitation processes.
To compute the stopping power induced by many collisions on electrons, the
Bethe-Bloch formula is used. A relativistic version of the Bethe-Bloch formula has
been proposed by Fano:
dE
dx
=
apie4Ztz
2
mev2
[
ln
(
2mev
2
< I >
)
− ln(1− β2)− β2 − C
Zt
− δ
2
]
(3.1)
where Zt is the target atomic number, z is the projectile atomic number, e the
electron charge, me the electron mass, v the projectile velocity, β = v/c where c is
the speed of light, C is a shell correction factor, δ a density effect correction and
< I > the mean ionization energy.
This last parameter is of crucial importance since it rules the energy loss of
the projectile and its range. It can be estimated from the chemical formula of the
material as follows:
ln(< I >) =
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i
ωiZi
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ln(Ii)
)
/
(∑
i
ωiZi
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)
(3.2)
where:
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• Zi and Ai are the charge and mass numbers for element i;
• ωi is the mass ration of element i in the material;
• Ii is the ionization energy of the element i.
It can be also determined from fits to experimental data. In this work, the
< I >= 75eV value for liquid water recommended by the ICRU, was used. A
variation of ∆ < I >= 5eV on the < I > value leads to a variation of around 1 mm
on the range.
According to the Bethe-Bloch formula, the rate of energy loss increases as the
particle energy decreases; therefore, ionization density will increase along the particle
path as it slows down. Near the end of the path, when most of its energy has been
lost, dE/dx reaches a maximum, corresponding to the peak in energy loss at low
energy,and then it drops to zero as the particle comes to rest. As already seen
in previous chapter, this behavior is characteristic of the way charged particles
distribute their energy in matter and it is called Bragg curve.
The elastic collisions with target nuclei and the Bremsstrahlung process are
neglected for hadron therapy applications.
3.3.1 Energy, range and angular straggling
As the heavy ion beam loses energy, it broadens in a variety of ways including energy,
position and angle.
For a beam of heavy ions, the Bragg peak spreads in energy and has a distinc-
tive width. The width of the Bragg peak is caused by the summation of multiple
scattering events that yield a Gaussian energy loss distribution often referred to as
energy straggling [45] :
N(E)dE
N
=
1
αpi1/2
exp
[
−(E − E¯)
2
α2
]
(3.3)
Energy straggling represents the specific number N(E) of particles having energies
in the range E to E+dE divided by the number of particles N , with mean energy E¯
after traversing a thickness x0 of absorber. The distribution parameter or straggling
parameter α is given by the expression [45] :
α2 = apiz2e4nZx0
[
1 +
KI
mv2
ln
(
2mv2
I
)]
(3.4)
where K is a constant depending on the electron shell structure of the absorber and
Z is its atomic number.
In an analogous manner, the range straggling2, expressed as the number of par-
ticles N(R) with ranges R to R+dR divided by the total number of particles of the
same initial energy, is given by the equation [45] :
N(R)dR
N
=
1
αpi1/2
exp
[
−(R− R¯)
2
α2
]
(3.5)
2The range of a charged particle is defined as the distance it travels before coming to rest.
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where R¯ is the mean range.
Upon entering a medium of thickness x0, a collimated beam experiences multiple
collisions that broaden the beam and cause it to diverge. This phenomena is called
angle straggling, and the mean divergence angle θ¯ s given by [45] :
θ¯2 =
2piz2e4
E¯2
nZ2x0ln
(
E¯a0
zZ4/3e2
)
(3.6)
where a0 is the Bohr radius:
a0 =
~2
kme2
(3.7)
The relative range straggling is smaller for heavier particles and also the lateral
spreading of the beam is smaller for heavy ions than the lateral spreading of protons.
3.4 Nucleus-nucleus collisions
When a heavy ion beam interacts with tissue, the interactions leave nuclei in an
excited state, and these excited nuclei decay by a variety of processes including
particle emission and deexcitation by photon emission. These secondary fragments
must be considered in therapy dose planning because they broaden the Bragg peak;
that is why nucleus-nucleus collisions play an important role in hadron therapy.
The nucleus-nucleus collisions can be schematically described by two steps: the
first is called the “entrance channel phase“ and the second step is called the “decay
phase“.
Figure 3.1: Schematic representation of a nucleus-nucleus collision.
The entrance channel phase is when a projectile hits a target nucleus and light
particles are promptly emitted and an excited quasi-projectile and an excited quasi-
target are formed. These excited nuclei decay through consecutive light particle
emissions (”evaporation” process) or by a simultaneous break-up (“fragmentation“
process); this is the decay phase.
For both steps (schematically represented in figure 3.1), several models have been
developed. A complete nucleus-nucleus collision modeling is achieved by a combi-
nation of a model describing the entrance channel and a model describing the decay
phase.
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Nucleus-nucleus collisions have two main effects. The first one is the disappear-
ance of the projectile since the collision will change its nature. As a consequence,
this projectile will not deposit its energy up to the Bragg Peak. The second effect is
the secondary particle production. These fragments will be often of smaller size but
with a velocity close to the velocity of the projectile. Because of the A/Z2 scaling
of the range for particles with the same velocity, these fragments will deposit their
energy at penetration depths beyond the projectile Bragg Peak forming the so called
”fragmentation tail“.
In GATE, as in Geant4, three models are implemented for nucleus-nucleus col-
lision:
• Abrasion-ablation model;
• Binary Light Ion Cascade model;
• Quantum Molecular Dynamic model.
The abrasion model is a simplified macroscopic model for nuclear-nuclear inter-
actions based largely on geometric arguments rather than detailed consideration of
nucleon-nucleon collisions. As such the speed of the simulation is found to be faster
than models such as G4BinaryCascade, but at the cost of accuracy. By default, in-
stead of performing an ablation process to simulate the de-excitation of the nuclear
pre-fragments, the Geant4 implementation of the abrasion model makes use of exist-
ing and more detailed nuclear de-excitation models within Geant4 (G4Evaporation,
G4FermiBreakup, G4StatMF) to perform this function. The abrasion interaction is
the initial fast process in which the overlap region between the projectile and target
nuclei is sheered-off. The spectator nucleons in the projectile are assumed to undergo
little change in momentum, and likewise for the spectators in the target nucleus.
Some of the nucleons in the overlap region do suffer a change in momentum, and
are assumed to be part of the original nucleus which then undergoes de-excitation.
Less central impacts give rise to an overlap region in which the nucleons can suffer
significant momentum change, and zones in the projectile and target outside of the
overlap where the nucleons are considered as spectators to the initial energetic in-
teraction.
The initial description of the interaction must, however, take into consideration
changes in the direction of the projectile and target nuclei due to Coulomb effects,
which can then modify the distance of closest approach compared with the initial
impact parameter. Such effects can be important for low-energy collisions.
The Geant4 Binary Cascade is an intranuclear cascade propagating primary and
secondary particles in a nucleus. Interactions are between a primary or secondary
particle and an individual nucleon of the nucleus, leading to the name Binary Cas-
cade. In binary cascade model, each participating nucleon is seen as a Gaussian wave
packet, and the total wave function of the nucleus is assumed to be direct product
of these. This wave form have same structure as the classical Hamilton equations
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and can be solved numerically. The Hamiltonian is calculated using simple time
independent optical potential. Two nuclei are prepared according to this model and
the lighter nucleus is selected to be the projectile. Nucleon in the projectile are en-
tered with position and momenta into the initial collision state. Until first collision
of each nucleon, its Fermi motion is neglected in tracking. Fermi motion and the
nuclear field are taken into account in collision probabilities and final states of the
collisions. Cross section data are used to select collisions. Where available, exper-
imental cross sections are used by the simulation. The cascade terminates when
the average and maximum energy of secondaries is below threshold. The remaining
fragment is treated by precompound and de-excitation models.
However, binary cascade model, the Hamiltonian is calculated from the simple time-
independent optical potential. A participant particle of the Binary Cascade is either
a primary particle including nucleons in the projectile nucleus or particles generated
or scattered in the cascade and only the participant particles are propagated in the
nucleus. Furthermore, scattering between participant particles is not taken into ac-
count. This is one of the reasons that using the model for a heavy ion reaction, is
not recommended.
Quantum Molecular Dynamics (QMD) [46] is the quantum extension of the
classical molecular-dynamics model and is widely used to analyze various aspects of
heavy ion reactions, especially for many-body processes, in particular the formation
of complex fragments.
There are three major differences between Binary Cascade and QMD: the definition
of a participant particle, the potential term in the Hamiltonian and the participant-
participant interactions.
The entire nucleons in the target and projectile nucleus are considered as par-
ticipant particles in the QMD model. Therefore each nucleon has its own wave
function, however the total wave function of a system is still assumed as the direct
product of them.
The potential terms of the Hamiltonian in QMD are calculated from the entire re-
lation of particles in the system, in other words, it can be regarded as self-generating
from the system configuration. On the contrary to Binary Cascade which tracks the
participant particles sequentially, all particles in the system are tracked simultane-
ously in QMD. Along with the time evolution of the system, its potential is also
dynamically changed. As there is no criterion between participant particle and oth-
ers in QMD, participant-participant scatterings are naturally included. Therefore
QMD accomplishes more detailed treatments of the above three points, however
with a cost of computing performance.
3.5 Physics list
On this section, the physics list used to perform the simulation is presented.
The electromagnetic processes have been carried out by using the StandardModel
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model, which has been widely validated and covers the range energy of interest for
hadron therapy applications. This model implements a variety of electromagnetic
processes for electron, positron, photon and charged hadrons interactions. The
electron ionization is implemented; it calculates the energy loss due to ionization for
electrons and positrons. The Bremsstrahlung energy loss contribution is calculated,
as also the energy loss due to electromagnetic processes for hadrons. Finally, the
MultipleScattering class simulates the multiple scattering of charged particles in
material after a given step, then it computes the mean free path length correction
and mean lateral displacement.
The hadronic processes are simulated using a generic elastic model for elastic
hadron scattering. For the inelastic processes, the Binary Cascade model has been
chosen for proton, and the QMD model has been chosen for ions.
For neutrons, the high precision inelastic and high precision capture models have
been chosen. Those models generate the final state for neutron inelastic scattering
and neutron capture using the high precision neutron model.
In table 3.1, the models used in the simulations for hadronic processes, are
summarized.
Hadronic processes
Particles Geant4 processes Geant4 models
Elastic scattering GenericIon G4HadronElasticProcess G4LElastic
all other particles G4UHadronElasticProcess G4HadronElastic
Inelastic process Protons G4ProtonInelasticProcess G4BinaryCascade
Inelastic process GenericIon G4IonInelasticProcess G4QMDReaction
Inelastic scattering Neutron G4NeutronInelasticProcess G4NeutronHPInelastic
Table 3.1: Models used in the GEANT4 simulations.
3.6 Parameters as used on the simulations for this work
The geometry of the simulation has been built in GATE setting a world geometry
as a cube 5 m per side.
The phantom is a cylinder of water with radius = 8 cm. Outside the cylinder the
material is air.
The source has been set as a rectangular beam 0.70 × 10 mm with an energy
Gaussian shape with 2 MeV σ. A beam divergency of 3 mrad has been taken into
account.
The dose map was collected by a parallelepiped DoseActor with dimensions
2×2×16 cm. The 16 cm in depth were divided in 160 bins, with a voxel dimension
in depth equal to 1 mm. The 2 cm along the lateral direction of the beam were
divided in 2000 bins, with a voxel dimension, along the lateral direction, of 10 µm.
The number of showers was 107 for all the simulation.
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In this Chapter, depth dose profiles and lateral dose profiles relating to a carbon
minibeams array will be discussed.
A cylindrical water phantom has been utilized to simulate the irradiation, using
planar sources of different energies. The computation of the absorbed dose is made
by dividing the phantom’s volume in voxels. Minibeam arrays have been simulated
with the aid of superposition algorithms.
The peak to valley dose ratios have been evaluated for different center-to-center
distances and configurations.
4.1 Introduction
As extensively discussed in previous chapters, the principle of MBRT is the dose-
volume effect: the dose that biological tissues can tolerate is higher the greater
the irradiated volume. By spatially dividing a single beam into an array of equally
distant minibeams, the process of reconstruction of the damaged vasculature spreads
from the tissue not directly irradiated to those in the beams’ trajectories. The
damage caused by the absorbed radiation is related to the absolute dose in the
peak (i.e. along the beams’ trajectories) and valley (between any two adjacent
minibeams). Accurately evaluating these doses is an extremely important aspect of
the therapy, and requires both direct (experimental) measures and their validation
via Monte Carlo simulations.
Besides the dose-volume effect, the technique studied in this work, is aimed to
achieve a high degree of conformity to the target volumes by exploiting the peculiar
characteristics of the dose deposition due to the use of heavy ions. Indeed, heavy
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ions offer an improved dose conformation as compared to photon and proton RT
because of a sharp increase of dose in a well defined depth (Bragg peak) and a rapid
fall-off beyond that maximum. In addition to a better sparing of normal tissue
structures close to the target, heavy ions exhibit a strong increase of the LET in
the Bragg peak as compare to the entrance region, with subsequent radiobiological
advantages.
4.2 Simulation geometry and details
Because of the peculiarities of MBRT in terms of dose-rate and spatial fragmenta-
tion irradiation method, Monte Carlo simulations are particularly important in the
development of the therapy.
The software described in Chapter 3, makes it possible to closely model the
experimental configuration necessary to analyze the relationship between dose dis-
tributions and various parameters, such as the beams’ energy and dimension, the
distance between minibeams, the depth the beam can reach inside the irradiation
volume, and the composition of the phantom.
The source used in the simulations reported in this chapter is represented by
planar minibeam 700 µm wide and 2 cm high impinging on a water phantom as
shown in figure 4.1. The phantom is a cylindrical volume 16 cm diameter and 16
cm long. The ideal area of the tumor is located after the center of the cylinder and
it is represented by a parallelepiped 1 cm deep and square section 2 cm side.
Figure 4.1: In the simulations, a minibeam impinges on a water cylinder from the
z-axis.
Several monochromatic beams, with energies ranging from 195 to 205MeV/nucleon,
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have been simulated. For every energy value, a Gaussian spectrum with 2 MeV
sigma, has been implemented. A divergence of the beam of 3 mrad has been taken
into account.
The goal is to cover the tumor volume using an array of minibeams. The array
is obtained from a single minibeam using a superposition algorithm. In order to
cover 2 cm, a certain number of beams need to be superimposed depending on the
center to center (c-t-c) distance between two adjacent beams. In the next table, the
number of beams in the array necessary to cover 2 cm, as a function of the c-t-c
distance, are summarized.
Number of beams in an array
c-t-c distance (µm) # of beams
1400 15
2100 10
2800 8
3500 6
Table 4.1: Number of beams as function of the c-t-c distance
As an example, in figure 4.2, are shown a single lateral profile beam and the
array lateral profile deriving from it.
Figure 4.2: Left panel: lateral profile of a 195 MeV/nucleon energy Carbon
minibeam at 1 cm depth. Right panel: minibeams array for 195 MeV/nucleon
energy Carbon minibeam at 1 cm depth and 1400 µm center-to-center distance.
In building the array, the minibeams are superimposed one to each other, giving
rise to the typical dose deposition profile characterized by peaks and valleys following
each other.
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4.3 Depth dose profiles for different energies
In figure 4.3 is shown the depth dose profile for a Carbon minibeam 195MeV/nucleon.
The Bragg peak is obtained at 8 cm depth. The dose deposited at 2 cm deep is
about the 30% of the dose deposited at the Bragg peak, while the 50 % of the Bragg
peak dose is reached very close to the Bragg peak itself.
Figure 4.3: Depth dose profile for a Carbon minibeam 195 MeV/nucleon
In order to cover a certain distance in depth with the Bragg peaks, it is necessary
to build a Spread Out Bragg Peak (SOBP). As already discussed in section 1.4,
Chapter 1, the SOBP is the aggregate of several pristine Bragg peaks at staggered
depths, and it can be obtained both in an active or passive way. Greater the energy,
deeper Bragg peak is obtained.
The goal was to cover 1 cm of tissue starting from 8 cm in depth. So, several
simulations have been performed changing the beam energy between 195 and 205
MeV/nucleon with 1MeV/nucleon step. Each simulation consider a monchromatic
beam. Adding together the data obtained with different beam’ energies, the SOBP
is obtained as in an active method.
In figure 4.4 are shown the depth dose distributions relating to different energy
beams and the SOBP as a linear combination of these. A uniform region of dose is
obtained between 8 and 9 cm. A flat physical dose at the SOBP is obtained by a
weighted sum of the single monochromatic beams dose deposition: the lower energy
beam should have a smaller weight because it leans on the plateau of dose due to
the higher energies.
At 2 cm deep, the dose deposited is 41% of the dose at the Bragg peak. Also, the
50% of the Bragg peak dose is obtained at 5.5 cm. Those values are obviously higher
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Figure 4.4: SOBP obtained by a weighted sum of the Bragg peaks from different
energies in the range between 195 and 205 MeV/nucleon.
than the previous value for a single energy beam, but they are still reasonable. A
good gain in the dose deposition, between the dose at the entrance and the dose at
the Bragg peak, is obtained also with a SOBP:
195 MeV/nucleon monochromatic beam 3.4
Spread Out Bragg Peak 2.6
Table 4.2: Gain of dose at the Bragg peak respect to the entrance.
Furthermore, as observable in figure 4.4 and as explained in previous chapters,
there is still a minor dose contribution behind the SOBP, which is due to lighter
fragments produced in nuclear reactions of the carbon projectiles with the target
material. This dose deposited is not negligible for the purposes of a treatment plan
because it is due to elements of significant biological impact.
4.4 Lateral dose profiles
Heavy charged particles show a small angular scattering leading to sharp lateral
boundary. This is of particular interest in the case of minibeams, because the
lateral spreading of the beam influences the dose deposition in valley region and so
the PVDR.
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In figure 4.5 is shown a 3-D representation of the carbon minibeam path for 195
MeV/nucleon. X-axis represents the beam’s path in depth and y-axis represents
the lateral distance. At the beginning of the path, the lateral dimension of the beam
is 0.7 mm, and it becomes much bigger at the Bragg peak because of the lateral
spreading.
Figure 4.5: Normalized depth dose deposition for a 195 MeV/nucleon Carbon
minibeam in water.
An alternative visualization is shown in figure 4.6, where the lateral profiles at
different depths for a 195 MeV/nucleon carbon minibeam are depicted. The data
were sampled at 1, 3, 5, 7 and 8 cm depth. This plot highlights how greater the
tails of the lateral distibution at deeper depths.
The dose in the valleys is strictly related to the extension of the tail in the
lateral distribution of the beam. Studying the penumbra of the beams will explain
the PVDR values discuss in next section.
Penumbra region is the rapid decrease at the edges of the radiation beam, and
it is usually defined as the space between the 80% and 20% lateral dose profile.
In order to study the penumbra along the beam path, the positions on the lateral
profile for the 80% and 20% (reported in figure 4.7) were recorded and compared.
The relative position of 20% regularly moves with increasing depth. This does
not happen for the relative position to 80% of the dose. This is because, with
increasing the depth, the initial shape of the beam is lost. The lateral profile of
the beam, which originally was rectangular, gradually assume a Gaussian shape and
that explains the particular trend. In any case, the distance between the position
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Figure 4.6: Lateral dose distribution for a 195 MeV/nucleon carbon minibeam at 1,
3, 5, 7 and 8 cm depth.
Figure 4.7: In red, is the position of the point at 80%, and in green is the position
of the point at 20% (first y axes). In yellow, is the difference between the previous
abscissas, so the value of the penumbra in terms of number of bins (second y axes).
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for the 80% of the dose and those relating to 20%, i.e. the value of the penumbra for
a given depth, is plotted in yellow, and denote the increase of the penumbra region
in depth.
According to the geometry of the collection matrix, every bins of the lateral pro-
file is 10µm: the penumbra values in µm is obtained by a conversion of the number
of bins, and it is reported in the next table.
Depth (cm) Penumbra (µm)
1 60 ± 10
3 140 ± 10
5 280 ± 10
7 380 ± 10
8 450 ± 10
Table 4.3: Penumbra values along the beam path.
In the Spread Out Bragg Peak, all the energies contributes to the lateral dose
profile. In figure 4.8 is shown a 3D representation of the dose distribution for
the SOBP obtained using minibeams with energy ranging between 195 and 205
MeV/nucleon. On this new configuration, the volume covered by the Bragg peaks
Figure 4.8: Normalized depth dose deposition for minibeams with energy ranging
between 195 and 205 MeV/nucleon.
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is 1 cm in depth, from 8 to 9 cm. A comparison between the 3D plot for the dose
deposition in the case of a single beam (Fig. 4.5) and in the case of a SOBP (Fig.
4.8), shown a higher dose along the beam path for a SOBP, as already explained in
the previous section.
Regard to the lateral spreading, any difference is noticeable between SOBP and
monochromatic beam, until the Bragg peak region. Indeed, on that region, a slight
widening is obtained between the lateral profile at 8 and 8.8 cm, as shown in figure
4.9
Figure 4.9: Lateral distribution at 8 and 8.8 cm in the SOBP. A slight widening is
obtained for the deepest position.
4.5 Minibeams array and Peak to valley dose ratio
An array is obtained by overlapping minibeams. An algorithm, starting from the
output data of the simulation, creates an array with a pre-defined center-to-center
distance. In this work, 1400, 2100, 2800 and 3500 µm c-t-c distances, are taken into
account. All of them are multiple of the minibeam width (700 µm).
In figure 4.10 is an example of depth dose distribution from an array of minibeams.
The energy is 195 MeV/nucleon and the c-t-c distance is 1400 µm. In this case, 15
minibeams are overlapping to form the array.
Initially the minibeams are well separated, it means that the dose is distributed for
the most along the beams path. In deep, the dose distribution starts to be signifi-
cant also in the region between two adjacent beams, due to the angular spreading
of the beams. At the Bragg peak the dose deposition, for a 1400 µm c-t-c distance,
is almost homogeneous.
In figure 4.11, are shown the lateral dose profile at the entrance and at the Bragg
peak. At the entrance, the lateral dose profile shows the dose deposited by every
beam, as well defined and spaced. At the Bragg peak instead, the lateral dose
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Figure 4.10: Normalized depth dose deposition for minibeams array with energy 195
MeV/nucleon and 1400 µm c-t-c distance.
deposition of each beam overlaps with the dose distribution of the beam next to
him. Clearly, the dose in the valley region is greater at the Bragg peak than at the
entrance, due to the beams superposition. Indeed, the valley dose at the entrance
is negligible but in the Bragg peak region this value goes up to the 50% of the dose
in the peak region.
The valley dose value depends, between others factors, on the depth and on the
c-t-c distance. This raising of the valley dose, reflects a decrement in the PVDR. In
figure 4.12, is reported the PVDR as a function of the depth for an array of Carbon
minibeams 195 MeV/nucleon and for the SOBP beam for different c-t-c distances.
The PVDR decrease rapidly after the entrance, as the valley dose start to increase.
In correspondence to the Bragg peak, the PVDR value grows; this is due to the
major increase on the dose deposition along the peak region.
In tables 4.4 and 4.5, are shown the PVDR values calculated at different depths
for a monochromatic beam (195 MeV/nucleon) and for the SOBP beam, as the
c-t-c distance changes. The PVDR trend in depth is similar for monochromatic
and SOBP beams. The only difference is visible at the Bragg peak, where a bigger
increase on the PVDR is obtained for monochromatic beams.
The aim of the radiation therapy is to spare normal tissues giving a solid amount
of dose at the target; this goal is reached with the minibeams irradiation technique,
when the PVDR values are bigger at the entrance and close to the unit at the Bragg
peak. To respect this principle, the best compromises, between the c-t-c distances
studied on this work, are 1400 and 2100 µm. For the two c-t-c distances mentioned
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Figure 4.11: Lateral dose profiles for an array of Carbon minibeams 195
MeV/nucleon and 1400 µm c-t-c distance, calculated at the entrance (in red) and
at the Bragg peak (in green).
above, the PVDR value is less than 10 at the Bragg peak and it is above 10 till 5.5
and 8 cm depth for 1400 and 2100 µm c-t-c distance respectively.
In particular, in the case of 1400 µm c-t-c distance, the dose at the target is
quasi-homogeneous with a PVDR of 1.8. But the PVDR decrease too rapidly from
79 at 1 cm depth to 3.4 at 7 cm depth, so PVDR values are not so high in normal
tissue. Conversely, for 2100 µm c-t-c distance, the PVDRs are higher in normal
tissues, starting from 224 at 1 cm depth to 29 at 7 cm depth. But in this case, the
PVDR is quite high at the Bragg peak too. Indeed a PVDR value of 8 is not enough
to ensure a quasi-homogeneous dose at the target.
In order to obtain a quasi-homogeneous dose at the target, an interlaced geom-
etry can be implemented as explained in the next section.
4.6 Minibeams interlaced arrays
A way to spare normal tissue and increase the dose at the target is to implement an
interlaced irradiation. The interlaced irradiation is obtained by sending two arrays
from opposite directions. The two arrays should be out of phase of half c-t-c distance.
In figure 4.13 are shown the depth dose depositions for two interlaced arrays and
different c-t-c distances, for a monochromatic minibeam 195 MeV/nucleon. The
two arrays interlace at the Bragg peak so the valleys of one array are filled with the
peaks from the opposite one. It means that a quasi-homogeneous dose distribution
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Figure 4.12: PVDR as function of depth for an array of Carbon minibeams 195
MeV/nucleon and for the SOBP beam for different c-t-c distances.
at the Bragg peak can be observed.
Looking at the lateral dose profiles (Fig. 4.14) obtained at the Bragg peak for
different c-t-c distances, in the interlaced geometry, a quasi-homogeneous dose is
obtained for the 1400 µm c-t-c distance. Increasing the c-t-c distance, the dose
appears as a follow of peaks and valleys again. The minimum of the dose at the
Bragg peak decrease from the 88 % (in the case of 1400 µm c-t-c) to the 23 % (in
the case of 3500 µm c-t-c) respect to the maximum dose, as shown in table 4.6.
Using an interlaced geometry, the 2100 µm c-t-c distance, seems to be the best
compromise between the c-t-c distances considered, with high values of the PVDR
in normal tissues and a quasi homogeneous dose at the target.
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PVDR: 195 MeV/nucleon energy beam
Depth 1400 µm c-t-c 2100 µm c-t-c 2800 µm c-t-c 3500 µm c-t-c
1 cm 79 ± 4 224 ± 11 362 ± 18 518 ± 26
3 cm 32 ± 2 62 ± 3 97 ± 5 148 ± 7
5 cm 13.1 ± 0.7 35 ± 2 51 ± 3 70 ± 3
7 cm 3.4 ± 0.2 16.5 ± 0.8 29 ± 1 40 ± 2
Bragg Peak 1.80 ± 0.09 8.0 ± 0.4 40 ± 2 89 ± 4
Table 4.4: PVDR values for 195 MeV/nucleon carbon minibeam.
PVDR: SOBP beam
Depth 1400 µm c-t-c 2100 µm c-t-c 2800 µm c-t-c 3500 µm c-t-c
1 cm 75 ± 4 211 ± 11 383 ± 19 509 ± 25
3 cm 33 ± 2 61 ± 3 102 ± 5 144 ± 7
5 cm 13.4 ± 0.7 34 ± 2 50 ± 3 70 ± 43
7 cm 3.3 ± 0.2 16.1 ± 0.8 29 ± 1 37 ± 2
Bragg peak 2.0-1.5 ± 0.1 8.6-6.2 ± 0.4 26-24 ± 1 36-44 ± 2
Table 4.5: PVDR values for SOBP.
Interlaced geometry - dose distribution at Bragg peak
percentage minimum dose
1400 µm 88%
2100 µm 76%
2800 µm 48%
3500 µm 23%
Table 4.6: Percentage minimum dose (referred to the maximum) at the Bragg peak
for two interlacing arrays at different c-t-c distances.
54 Chapter 4. Carbon minibeam: simulations and results
Figure 4.13: 3-D representation of the depth dose distribution for an interlaced
geometry for different c-t-c distances.
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Figure 4.14: Lateral dose profile at the Bragg peak, for two interlacing arrays at
different c-t-c distances.
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In this Chapter, the lateral and depth dose profiles relating to an oxygen minibeams
array will be discussed.
As previously done for carbon calculations, a planar minibeam 700 µm wide and
2 cm high impinging on a water cylindrical phantom (as shown in figure 4.1) was
used.
The simulations were carried out for different beam energies ranging from 233
to 241 MeV/nucleon.
As for the carbon calculations, arrays have been obtained starting from a sin-
gle beam, through an overlap algorithm. Moreover, summing the Bragg peaks for
different energies, the spread out Bragg peak has been obtained. The PVDR were
calculated for different array configurations at different c-t-c distances.
5.1 Depth dose profiles for different energies
In order to reach the same depth as done with carbon, an oxygen beam 233.5
MeV/necleon as been used. In figure 5.1, the depth dose distribution for such a
beam is shown. The Bragg peak is located at 8 cm depth. The dose deposited at 2
cm depth is about 23% of the dose deposited at Bragg peak.
As done before for the case of carbon minibeams, is necessary to achieve a SOBP
by superimposing different Bragg peaks at various energies, in order to obtain a
distribution of depth dose covering 1 cm in volume and centered at about 8.5 cm
depth. To do so, minibeams of energy between 233.5 and 241.5 MeV/nucleon were
simulated; their sum is shown in figure 5.2
The dose rate at 1 cm depth is about 39% of the dose at the SOBP, and the
50% of the dose is obtained from about 6 cm depth.
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Figure 5.1: Depth dose distribution for a 233.5 MeV/nucleon oxygen beam (in red).
Figure 5.2: SOBP obtained by a weighted sum of the Bragg peaks from different
energies in the range between 233.5 and 241.5 MeV/nucleon.
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Energy (MeV) Weight
233 0.13
243 0.13
235 0.14
236 0.15
237 0.16
238 0.18
239 0.22
240 0.3
241 1
Table 5.1: Weights used for the composition of the SOBP.
The most significant energy in the SOBP composition is the highest one, as
shown in table 5.1, were the relatives weight of each monochromatic beam are re-
ported.
The difference between the dose distributions relating to carbon ions and oxygen
ions, is given by the dose tail after the Bragg peak. This tail is due to nuclear
fragmentation of the beam and the dose deposited by the fragmentation products.
Furthermore, in order to reach the same depth, the oxygen ions must have an energy
greater than the carbon ions. This increase in energy affects the amount of dose
deposited after the Bragg peak. In the case of oxygen, which is an heavier ion than
carbon, this tail appears to be greater than a 2%.
5.2 Lateral dose profiles
The extent of lateral dose deposition depends on the angular scattering of the par-
ticles. The lateral scattering increases changing the lateral profile of the beam, as
the depth increases.
In figure 5.3, the dose profiles for an oxygen-minibeam with 233MeV/nucleon
energy at different depths, are shown. At 1 cm depth, the initial shape of the
minibeam appears as a plateau with sharp boundaries. Increasing the depth, the
lateral dose profile turns into a Gaussian distribution. As in the case of the figure,
for a monochromatic beam 233 MeV/nucleon energy, the Bragg peak is obtained
at 8 cm depth, where the major dose deposition is achieved, and the FWHM of the
curve is 0.44 mm.
The lateral dose profile, for a SOBP beam, is due to the superposition of the
lateral profile for different energies. In figure 5.4, are shown the lateral dose profiles
obtained at the same depth (8.0 cm) for different energies, taking into account
the weight value in table 5.1 for the composition of the SOBP. Clearly, the most
significant energy is the one at 241.5 MeV/nucleon.
Comparing the lateral dose profile for a monochromatic beam 233.5MeV/nucleon
and for the SOBP beam (Fig. 5.5), the only difference is on the tails of the distri-
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Figure 5.3: Lateral beam profiles at different depth for an oxygen beam 233
MeV/nucleon energy.
Figure 5.4: Contributions to the lateral dose profile, due to beams with various
energies, at 8.0 cm depth.
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bution. For a SOBP beam, those tails are higher and this influences the valley dose.
Figure 5.5: Comparison between the lateral dose deposition for a monochromatic
beam 233.5 MeV/nucleon and for the SOBP beam at 8.0 cm depth.
A study of the penumbra was made, showing the same trend as the previously
one for carbon ions. The penumbra values in depth are depicted in figure 5.6.
5.3 Minibeams array and Peak to Valley Dose Ratios
As for Carbon’s beam, a code was implemented to calculate the superimpositions
of the beams to create an array. The trend of the PVDR in depth can be described
by a decreasing curve as shown in figure 5.7, where the PVDR in depth is depicted
for an oxygen beam energy 233 MeV/nucleon.
The biggest PVDR is obtainend at the entrance, after that it starts to decrease.
At about the half depth, it is still 100. It reaches his minimum just before the Bragg
peak. At the Bragg peak, there is a slight raise. This increase on the PVDR, it
is due to the significant increment on the peak dose. Also the valley dose has an
increment at the Bragg peak, but it is not so sharp as for the peak dose. In figure
5.8, a comparison between dose deposition in along the peak region and along the
valley region, is shown.
In order for the therapy to be effective, the valley dose should always be below the
threshold dose for the considered tissue. And the valley dose is strongly dependent
on the center-to-center distance.
As in the previous case of Carbon’s beam, the c-t-c distances 1400 µm, 2100 µm,
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Figure 5.6: Penumbra values in depth for a monochromatic oxygen beam (237.5
MeV/nucleon).
Figure 5.7: PVDR trend as function of depth in water, for an oxygen beam 233
NeV/nucleon energy.
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Figure 5.8: Peak and valley dose deposition are shown separately. The dose deposited
in the peak region is shown in red and the scale is at the left side of the plot. For the
dose deposited along the valley region (in green), the scale is reported at the right
side of the plot.
2800 µm, 3500 µm were considered. In figure 5.9 are shown two plots: at left is the
dose deposition in depth in the valley region, and at right is the PVDR in depth,
for different c-t-c distances. A greater valley dose deposition at the Bragg peak
for the 1400 µm c-t-c distance configuration, reflects on a PVDR in depth without
increment at the Bragg peak. Widening the c-t-c distance, the dose deposited in
valley region become lower, and this induces the presence of an increment in the
PVDR at the Bragg peak.
For every c-t-c distance, the PVDR was calculated, the results are shown in table
5.2 for a monochromatic beam 233.5 MeV/nucleon energy, and in table 5.3 for the
SOBP beam.
PVDR: 233.5 MeV/nucleon energy beam
Depth 1400 µm c-t-c 2100 µm c-t-c 2800 µm c-t-c 3500 µm c-t-c
1 cm 77 ± 4 260 ± 13 490 ± 24 670 ± 33
3 cm 32 ± 2 70 ± 4 125 ± 6 207 ± 10
5 cm 16.2 ± 0.8 35 ± 2 54 ± 3 81 ± 4
7 cm 4.7 ± 0.2 20 ± 1 31 ± 2 43 ± 2
Bragg Peak 2.6 ± 0.1 17.4 ± 0.8 58 ± 3 90 ± 4
Table 5.2: PVDR values for 233 MeV/nucleon oxygen minibeam.
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Figure 5.9: (A) Valley dose in depth for different c-t-c distances. (B) PVDR in
depth for different c-t-c distances. These data refer to an oxygen minibeam 233
MeV/nucleon.
PVDR: SOBP beam
Depth 1400 µm c-t-c 2100 µm c-t-c 2800 µm c-t-c 3500 µm c-t-c
1 cm 74 ± 4 243 ± 12 470 ± 23 660 ± 33
3 cm 31 ± 2 71 ± 4 129 ± 6 213 ± 11
5 cm 16.5 ± 0.8 35 ± 2 55 ± 3 81 ± 4
7 cm 5.0 ± 0.2 20 ± 1 31 ± 2 44 ± 2
Bragg peak 2.7-2.3 11-12 25-43 35-68
Table 5.3: PVDR values for SOBP.
As previously stated, the PVDR start from a maximum value at the entrance
and decreases along the beam path, this is mainly due to the lateral spreading
in depth and, consequently, to a rise on the valley dose. For the narrower c-t-c
distance (i.e. 1400 µm), the increment in valley dose is quite high, so it is preferable
to choose a wider c-t-c distance in order to keep the valley dose in normal tissue
as low as possible. The drawback due to the use of c-t-c distances greater than
1400 µm is the increase of the PVDR at Bragg peak. Indeed, a lower PVDR would
be appropriate at the Bragg peak so that the dose would be as homogeneous as
possible. Anyhow, an homogeneous dose can be reached in the tumor volume,
interlacing beams originating from different positions, as explained in next section.
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5.4 Minibeams interlaced arrays
Two arrays of minibeams coming from opposite direction interlace at the Bragg
peak. This lets to a more homogeneous dose at the Bragg peak.
In figures 5.10 and 5.11, the 3-dimensional depth dose distribution and the lateral
profiles at the Bragg peak for the interlaced geometry at different c-t-c distances,
are respectively represented.
From the figures, an homogeneous dose deposition at the Bragg peak results for
the 1400 µm c-t-c distance. Also, the dose deposited in the interlaced geometry,
results to be twice the average dose in the case of a single array.
Increasing the c-t-c distance to 2100 µm, the dose for the interlaced geometry,
can be still considered homogeneous because the lower value is still over the 80% of
the maximum dose.
For the larger c-t-c distances, 2800 and 3500 µm, the new dose distribution at
the Bragg peak due to the interlaced geometry, can be seen as a new array with
smaller c-t-c distance. To obtain an homogeneous dose it is necessary to use more
arrays of minibeams coming from other directions.
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Figure 5.10: 3-D representation of the depth dose distribution for an interlaced
geometry for different c-t-c distances.
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Figure 5.11: Lateral dose profile at the Bragg peak at different c-t-c distances: for
an interlaced geometry (in green), and for a single beam (in red).
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Carbon and oxygen beams in water have been simulated with the aim of evalu-
ating the dose deposition in depth, the lateral dose profiles at different depths, and
the ratio of the peak-to-valley doses, being the PVDR a very relevant dosimetric
parameter.
Carbon and oxygen present the typical Bragg curve for the dose deposition; in
figure 6.1 the depth dose deposition for a carbon beam 200 MeV/nucleon and an
oxygen beam 237.5 MeV/nucleon are shown.
Figure 6.1: Depth dose deposition in logarithmic scale for a carbon beam 200
MeV/nucleon and an oxygen beam 237.5 MeV/nucleon.
For those energies, the Bragg peak is obtained at 8.5 cm for both ions. The
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main difference for the two beams lies on the dose deposited after the Bragg peak
due to the fragmentation processes. This tail beyond the Bragg peak is higher for
oxygen ions than for carbon ions.
From the simulations, was also possible to study the lateral spreading of the
beams. In figure 6.2 are shown the lateral dose profiles at the Bragg peak for both
the ion beams. Carbon beam presents a lateral spreading larger than oxygen, due
Figure 6.2: Lateral dose deposition for a carbon beam 200 MeV/nucleon (in red)
and an oxygen beam 237.5 MeV/nucleon (in green).
to a greater angular spreading.
At the same way, the data for the penumbra show bigger values for carbon beam
than for oxygen beam. In figure 6.3, the values of the penumbra calculated along
the beam path, are shown for carbon and oxygen minibeams.
The study on lateral spreading for the two ions, is the first step towards the
study of the most important parameter for the technique: the PVDR.
In figure 6.4 are shown the PVDR in depth at different c-t-c distances for both
carbon and oxygen ions.
The PVDR values for oxygen are always greater than for carbon, with the ex-
ception of the Bragg peak region for 1400 µm c-t-c distance.
For both ions, the suitable c-t-c distance seems to be 2100 µm. This is the
distance with the best compromise between high PVDR at the entrance and low
PVDR at the target.
An important factor that will make the difference between the two ions is the
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Figure 6.3: Penumbra values as a function of depth for a carbon beam 200
MeV/nucleon (in red) and an oxygen beam 237.5 MeV/nucleon (in green).
RBE. Since RBE of charged particles is increased by increasing the particle ioniza-
tion density, biological effectiveness is close to that of x-rays in the entrance channel
where normal tissue is exposed, and is high in the Bragg peak region where the
tumor is located.
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Figure 6.4: PVDR values as a function of depth for a carbon and oxygen minibeam
arrays, at different c-t-c distances.
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6.1 Comparison with x-rays minibeams
In a study on minibeam radiation therapy conducted at the ESRF [29], Monte Carlo
simulations were used to calculate penumbra and PVDR in the healthy tissues and
in the tumor for different beam energies. On that work, x-rays 600 µm minibeam
size and 1200 µm c-t-c separation were considered.
For x-rays with energy between 100 and 500 keV and c-t-c distance of 1200 µm,
penumbra values at the target (7 cm depth) were found to be between 20 ± 1 µm
and 230 ± 11 µm, corresponding to the 3% and 38% of the initial beam width.
Those values are much smaller than the values found for carbon and oxygen ions
that are between 400-450 µm (≈ 60% of the initial beam width).
The PVDR values have been found to be much smaller for x-rays than for carbon
and oxygen. For x-rays, the PVDRs range between 7.8 at the target for 500 keV
and 34 at the entrance for 400 keV . The PVDR found with the simulation in this
work are much bigger, ranging between 1.8 at the target and 79 at the entrance, for
carbons; and ranging between 2.6 at the target and 77 at the entrance, for oxygen
(those values are referred to a c-t-c distance of 1400 µm).
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Among the recent techniques in the treatment of cancer is the use of a perforated
grid in radiation therapy.
Ko¨hler was the first to report on the use of a grid in x-ray therapy in 1909.
The literature contains no other reference to this form of treatment until 1933,
when Liberson, unaware of the previous report, developed the same idea. He found
that the skin could tolerate larger doses and would recover more quickly when the
radiation was delivered through a grid [47].
In Grid therapy the radiation is delivered using a grid-like pattern of small beams,
and it enables delivery of higher tumor doses while minimizing radiation-induced
skin damage.
Grid therapy is based on the dose-volume effect, in which dose delivered to a
continuous region induces greater cell damage than the same dose fractionated in
space. As for microbeam therapy in which reducing a radiation beam diameter from
1 mm to 25 µm increased the threshold dose for destruction of cells along the beam
path, the parts of the tissue that are not irradiated can help repair areas that are
irradiated.
Previous studies have used a single photon field to deliver the grid pattern,
resulting in the dose distribution of peaks and valleys being applied to both normal
tissue and the tumor. Whilst this approach does indeed improve normal tissue
sparing, it also reduces the therapeutic effect to the tumor.
The idea is to use protons pencil beams to create grid-like entrance doses, while
ensuring homogeneous dose coverage of the target volume.
7.1 Simulation parameters
As for the case of carbon and oxygen minibeams, a cylindrical water geometry was
implemented. To collect data, two boxes with dimension 1 × 1 cm along x and y
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directions, and 1 mm in depth (z direction), were used. One of the boxes was placed
at the entrance (1 cm deep), and the second one was placed at the Bragg peak.
The source was a square proton minibeam 700 µm per side. For the energy of
the beam a Gaussian distribution with 2 MeV σ was implemented. The central
energy was 105 MeV .
The dose was collected inside the boxes above, by a doseActor (section 3.2.3).
The box was divided in 1000 × 1000 × 1 voxels. So the voxel shape is a cube with
dimension of 1 mm per side.
The number of primary showers was 107.
7.2 Depth dose curve
In this section the depth dose distribution for proton beams of 105 MeV energy are
presented. In figure 7.1 the depth dose curve for one complete array of minibeams
is shown. The Bragg peak is obtained at 8.2 cm depth, negligible dose is deposited
at depths higher than 9 cm. The data plotted in figure 7.1 were collected in voxels
Figure 7.1: Depth dose curve for an array of proton minibeams 105 MeV energy.
Data were sampled with voxels 2cm× 2cm× 1mm.
of 2cm× 2cm× 1mm dimension to cover the whole array so both the primary and
scatter beams are taken into account.
In figure 7.2 is shown the depth dose profile for a single proton minibeam 105
MeV energy. In this case the voxels size is 700µm × 700µm × 1mm. The shape
differs from the standard depth dose curve for protons due to the high ratio of the
lateral scattering with respect to the dose deposited by the primary beam.
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Figure 7.2: Depth dose curve for an array of proton minibeams 105 MeV energy.
Data were sampled with voxels 700µm× 700µm× 1mm.
7.3 Grid simulations
A square proton minibeam with dimensions 700 µm per side, energy 105 MeV and
impinging on a cylinder of water, was simulated. The arrays of square minibeams
was creating through an algorithm. The c-t-c distances 1400, 2100, 2800 and 3500
µm have been considered.
In figure 7.3, are shown the lateral dose deposition for an array with 1400 µm
c-t-c distance, at the entrance (1 cm depth) and at the Bragg peak.
At the entrance, the grid geometry is well defined, every single beam composing
the array can easily be distinguished. At the Bragg peak, the angular spreading
of the beams, leads to a homogeneous dose and the single beams cannot be distin-
guished anymore.
Increasing the c-t-c distance to 2100 µm, the dose at the Bragg peak is still
homogeneous, as shown in figure 7.4. For the other c-t-c distances, 2800 (Fig. 7.5)
and 3500 (Fig.7.6) µm, the dose at the Bragg peak is less homogeneous, but the
PVDR are still small as shown in table 7.1, where the PVDR for different c-t-c
distances are reported.
For this configuration, the 2100 µm c-t-c distance, seems to be the most favorable
one, since produce a PVDR of about 1 at the Bragg peak and a much higher value
of 300 at the entrance.
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Figure 7.3: Lateral dose deposition for an array of proton minibeams with 1400 µm
c-t-c distance, at the entrance (left) and at Bragg peak (right).
Figure 7.4: Lateral dose deposition for an array of proton minibeams with 2100 µm
c-t-c distance, at the entrance (left) and at Bragg peak (right).
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Figure 7.5: Lateral dose deposition for an array of proton minibeams with 2800 µm
c-t-c distance, at the entrance (left) and at Bragg peak (right).
Figure 7.6: Lateral dose deposition for an array of proton minibeams with 3500 µm
c-t-c distance, at the entrance (left) and at Bragg peak (right).
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PVDR values
c-t-c distance (µm) Entrance Bragg peak
1400 60 ± 3 1.0 ± 0.1
2100 310 ± 15 1.0 ± 0.1
2800 850 ± 40 1.5 ± 0.1
3500 3000 ± 150 2.0 ± 0.2
Table 7.1: PVDR values for an array of proton minibeams at different c-t-c distances.
Discussion
Minibeam radiation therapy (MBRT) is a technique that explores the limits of the
dose volume effect by the use of submillimetric field sizes in combination with the
spatial fractionation of the dose.
MBRT with synchrotron x-ray is presently under development at Brookhaven
National Laboratory and at the European Synchrotron Radiation Facility.
This thesis work has been devoted to the study of MBRT with heavy ions instead
of x-rays. In particular Carbon and Oxygen beams have been taken into account.
The aim was to put together the advantages of spatially fractionated techniques
with the advantages of a better ballistic typical of hadrontherapy.
By means of Monte Carlo simulations, the depth dose distributions, the lateral
distributions, the Peak-to-Valley-Dose ratios (PVDR) were calculated for carbon
and oxygen beams at different energies and different center-to-center distances.
As a result, a slightly larger lateral spreading for carbon, leading to larger values
on the penumbra of the beam respect to the oxygen case, was found. A bigger
tail deposition beyond the Bragg peak due to fragmentation process, was found for
oxygen.
Finally the study of the PVDR as function of the center-to-center distance be-
tween the minibeams, point at 2100 µm as the best compromise between giving a
quasi-homogeneous dose at the target and sparing normal tissues, for the center-to-
center distances taken into account in this study.
From a comparison with x-rays minibeams data, was found that heavy ions pro-
duce larger penumbras. On the contrary, PVDRs were found to be more competitive,
since higher values were found at the entrance and smaller values were found at the
target.
Among the spatially fractionated techniques grid therapy should be included.
Even in the case of the grid therapy, the concept has been revised considering the
use of protons instead of x-rays. From the simulations was proved the possibility
to obtain a homogeneous or quasi-homogeneous dose at the target while retaining
high values of PVDR along the beam path, for all the center-to-center distances
considered.
In conclusion, this proof of concept has demonstrated that spatially fractionated
techniques such as MBRT and grid can also be implemented with the use of ions
instead of x-rays, exploiting the advantages of hadrontherapy.
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